Rytary (levodopa/carbidopa extended-release capsule) / Amneal 
Welcome,         Profile    Billing    Logout  
 0 Diseases   1 Trial   1 Trial   75 News 
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Amneal
    Trial completion date, Trial primary completion date:  Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) -  Feb 8, 2023   
    P2,  N=60, Recruiting, 
    ClinicalTrials.gov Identifier: NCT03670953. Trial completion date: Jan 2023 --> Jan 2024 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Parkinson’s Disease Patient Characteristics in a US Real-World Study of Opicapone () -  Oct 17, 2022 - Abstract #ANA2022ANA_605;    
    While the study was conducted during the ongoing pandemic and investigators could initiate treatment via telemedicine, most investigators elected to initiate patients on opicapone with an in-person visit. Findings from OPTI-ON will further characterize the PD population treated with opicapone and real-world clinician- and patient-reported outcomes data in the US will complement results from previous controlled clinical trials.
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Amneal
    Learning and predicting Levodopa regimens from wearable sensors: A novel machine learning approach () -  Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_1532;    
    Our wearable-based RL policies suggest that the original n=26 study patients would experience lower bradykinesia (and unchanged dyskinesia) if switched to controlled-release L-dopa formulations such as Rytary... We show that pairing machine learning with even small quantities of wearable movement tracker data can offer novel, generalizable clinical insights and medication strategies, which can be used to improve care for other PD patients for whom wearable data are not available.
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Amneal
    Reimbursement, Journal, Medicare:  Difference in rural and urban Medicare prescription pattern for Parkinson's disease in Hawai'i. (Pubmed Central) -  May 7, 2022   
    In the state of Hawai'i, there is an urban-rural access gap to neurologists as evidenced by Medicare prescription pattern. Further study is needed to understand the reasons for rural-urban differences in prescription patterns and their impact on outcomes.
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Amneal
    Journal:  Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®). (Pubmed Central) -  Nov 24, 2021   
    Further study is needed to understand the reasons for rural-urban differences in prescription patterns and their impact on outcomes. In the ADVANCE-PD trial, CD-LD ER significantly increased ON time per dose compared to CD-LD IR (+1.21 h, p < 0.0001) and provided significantly more ON time per dose (3.55 h vs 2.38 h, p < 0.0001).
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Amneal
    Enrollment open:  Novel Non-opioid Post-surgical Pain Treatment in Females (clinicaltrials.gov) -  Nov 18, 2021   
    P2,  N=60, Recruiting, 
    In the ADVANCE-PD trial, CD-LD ER significantly increased ON time per dose compared to CD-LD IR (+1.21 h, p < 0.0001) and provided significantly more ON time per dose (3.55 h vs 2.38 h, p < 0.0001). Not yet recruiting --> Recruiting
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Amneal, entacapone/levodopa/carbidopa / Generic mfg.
    [VIRTUAL] Characteristics of prescribers for Parkinson’s disease patients: A nationwide study on 2017 Medicare data () -  Sep 20, 2020 - Abstract #MDSCongress2020MDS Congress_239;    
    Primary care specialties, including internal medicine, family medicine, and nurse practitioners, comprise the majority of prescribers for PD patients in the US. Advanced neurotherapeutic education and decision support guidelines for these providers may help to improve PD care in the US.
  • ||||||||||  Rytary (levodopa/carbidopa extended-release capsule) / Impax
    Clinical, Journal:  Efficacy of carbidopa-levodopa extended-release capsules (IPX066) in the treatment of Parkinson Disease. (Pubmed Central) -  Sep 4, 2019   
    IPX066 may also improve the patient´s compliance due to its simplified drug regimen. The marketing of IPX066 outside the US is complex since in countries like Germany, health-care payers only consider innovation in terms of mode of action whereas innovation of pharmacokinetic and pharmacodynamic properties is disregarded.
  • ||||||||||  Inbrija (levodopa inhalation powder) / Acorda
    Journal:  Inhaled levodopa (Inbrija) for Parkinson's disease. (Pubmed Central) -  Aug 6, 2019   
    The marketing of IPX066 outside the US is complex since in countries like Germany, health-care payers only consider innovation in terms of mode of action whereas innovation of pharmacokinetic and pharmacodynamic properties is disregarded. No abstract available
  • ||||||||||  levodopa/carbidopa extended-release capsule (IPX203) / Amneal
    Trial completion, Enrollment change, Trial primary completion date, Metastases:  A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's Disease (clinicaltrials.gov) -  Jan 18, 2017   
    P2,  N=26, Completed, 
    Phase classification: P1/2 --> P2 | Initiation date: Feb 2009 --> Nov 2008 Active, not recruiting --> Completed | N=51 --> 26 | Trial primary completion date: Dec 2016 --> Aug 2016